Donald J. Zurbay

President and CEO at PDCO

Board

Since October 2022

Age

57 years

Tenure

Started as CFO in June 2018 and was promoted to President and CEO in October 2022.

Also at PDCO

KMB

Kevin M. Barry

Chief Financial Officer (CFO)

KMP

Kevin M. Pohlman

Chief Operating Officer (COO)

LBK

Les B. Korsh

Chief Legal Officer

About

Donald J. Zurbay has been leading PDCO as President and Chief Executive Officer since October 2022 after serving as the Chief Financial Officer from June 2018 to October 2022. His extensive career in finance and leadership includes pivotal roles at St. Jude Medical, Inc. where he served as Vice President and CFO, as well as significant stints at PricewaterhouseCoopers, The Valspar Corporation, and Deloitte & Touche.

Throughout his professional journey, he has demonstrated strategic financial oversight and leadership acumen, contributing to growth and transformation at every organization he has been part of. In addition to his executive roles, he has also served on the boards of multiple companies including Avedro, Inc., Silk Road Medical, Inc., and Sight Sciences, Inc., which further underscores his broad expertise in both finance and the healthcare sector.

At 57 years old, he brings a wealth of experience and insight to PDCO, balancing deep industry knowledge with a commitment to innovative leadership. His career reflects a steady progression from financial management roles to executive leadership, making him a central figure in PDCO’s strategic direction.

$PDCO Performance Under Donald J. Zurbay

Past Roles

Organization	Role	Date Range	Details
Patterson Companies, Inc. (PDCO)	Chief Financial Officer (CFO)	June 2018 – October 2022	Served as CFO before promotion to President and CEO
Patterson Companies, Inc. (PDCO)	Interim Chief Financial Officer	Brief period during transition	Served during the transition period before officially becoming CEO
St. Jude Medical, Inc.	Vice President and Chief Financial Officer	August 2012 – January 2017	Oversaw accounting, financial, and business development; also held roles as Director of Finance and Corporate Controller
PricewaterhouseCoopers	Assurance & Business Advisory Services Senior Manager	5 years	N/A
The Valspar Corporation	General Accounting Manager	N/A	N/A
Deloitte & Touche	Auditor	Started in 1989	N/A
Avedro, Inc.	Director	February 2019 – November 2019	Role concluded with the company’s sale

External Roles

Organization	Role	Date Range	Details
Sight Sciences, Inc.	Director	Since July 2020	Current board seat
Silk Road Medical, Inc.	Director	Since March 2018	Current board seat

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$900,001	Annual	Base Salary
All Other Compensation	$118,674	Annual	Breakdown: Automobile Allowance ($10,596), Executive Life Insurance Premiums ($5,409), Reimbursement for Taxes ($8,194), 401(k) Contributions ($12,641), Travel Benefit ($3,889), Dividends ($77,944)

Performance Compensation

Data from FY 2024

Annual Cash Incentive Compensation (MICP)

Metric	Threshold	Target	Maximum	Weight
Consolidated Adjusted Operating Income	$289.4M	$340.4M	$408.5M	70%
Consolidated Free Cash Flow	$149.1M	$175.4M	$210.5M	30%

Target MICP Award: $1,125,000 (125% of base salary)
Actual Payout: $813,713 (72.33% of target)
Evaluation Period: Fiscal 2024
Conditions: Payout is contingent on achieving the specified financial metrics; if performance falls below the threshold, no payout is made.

Performance Stock Units (PSUs)

Metric	Threshold	Target	Maximum
3-Year Cumulative EPS	90% of target (50% payout)	100% (100% payout)	115% (160% payout)
rTSR Modifier	0.75x	1.00x	1.25x

PSU Grants (Units): Threshold: 22,550, Target: 60,132, Maximum: 120,264
Grant Date: July 1, 2023
Grant Date Fair Value: $2,063,129
Vesting Schedule: Vesting occurs after a 3-year performance period (fiscal 2024–2026)

Stock Options

Detail	Value
Grant Date	July 1, 2023
Grant Date Fair Value	$1,000,000
Grant Date Stock Price	$33.26 per share
Vesting Schedule	One-third annually over 3 years (starting July 1, 2024)
Expiration Date	July 1, 2033
Performance Metrics	None – service-based

Restricted Stock Units (RSUs)

Detail	Value
Grant Date	July 1, 2023
Grant Date Fair Value	$999,995
Number of RSUs Granted	30,066
Grant Date Stock Price	$33.26 per share
Vesting Schedule	One-third annually over 3 years (starting July 1, 2024)
Performance Metrics	None – service-based